Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Youley Tjendra

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
American Journal of Clinical Pathology|March 5, 2026
Utility of intraoperative frozen section analysis in risk stratification and surgical decision-making for salivary gland neoplasms of uncertain malignant potentialJaylou M Velez Torres, Yesica G Miltos, Youley Tjendra, et al.
Cancer Cytopathology|April 9, 2024
Exploring the atypia of undetermined significance: Malignant ratio, ThyroSeq v3 positive call rate, molecular-derived risk of malignancy, and risk of malignancy as possible quality metric tools in thyroid cytologyJaylou M Velez Torres, Porshya M Curnow, Youley Tjendra, et al.
Cancer Cytopathology|September 13, 2023
Don't SUMP it! Utility of PLAG1 immunocytochemistry in basaloid SUMP subcategoryMonica Sanchez-Avila, Youley Tjendra, Yiqin Zuo, et al.
Cancers|January 28, 2026
Tumor Growth Rate Predicts Pathological Outcomes in Breast Fibroepithelial Tumors: A Pilot Study and Review of LiteratureHisham F Bahmad, Adriana Falcon, Abdallah Araji, et al.
Annals of Surgical Oncology|March 18, 2022
Axillary Response to Neoadjuvant Therapy in Node-Positive, Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients: Predictors and Oncologic OutcomesOrli Friedman-Eldar, Tolga Ozmen, Salah James El Haddi, et al.
Cancer Cytopathology|July 1, 2022
Probability of malignancy as determined by ThyroSeq v3 genomic classifier varies according to the subtype of atypiaDavid C Gajzer, Youley Tjendra, Darcy A Kerr, et al.
Science Translational Medicine|November 5, 2025
DLL1-responsive PD-L1<sup>+</sup> tumor-associated macrophages promote endocrine resistance in breast cancerShailesh Singh, Claudia Weindorfer, Ajeya Nandi, et al.
Cancer Cytopathology|September 11, 2024
Parsing the thyroid cytopathology suspicious for malignancy diagnosis through molecular-derived risk of malignancy and other related parameters: Insights into nodule characteristics and practice patternsDavid Starr, Youley Tjendra, Jaylou M Velez Torres, et al.
Blood|November 26, 2015
Active IKKβ promotes the stability of GLI1 oncogene in diffuse large B-cell lymphomaNitin K Agarwal, Chae H Kim, Kranthi Kunkalla, et al.
Cancer Cytopathology|April 9, 2024
Atypia of undetermined significance and ThyroSeq v3-positive call rates as quality control metrics for cytology laboratory performanceOdille Mejia-Mejia, Andres Bravo-Gonzalez, Monica Sanchez-Avila, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
American Journal of Clinical Pathology|March 5, 2026
Utility of intraoperative frozen section analysis in risk stratification and surgical decision-making for salivary gland neoplasms of uncertain malignant potentialJaylou M Velez Torres, Yesica G Miltos, Youley Tjendra, et al.
Cancer Cytopathology|April 9, 2024
Exploring the atypia of undetermined significance: Malignant ratio, ThyroSeq v3 positive call rate, molecular-derived risk of malignancy, and risk of malignancy as possible quality metric tools in thyroid cytologyJaylou M Velez Torres, Porshya M Curnow, Youley Tjendra, et al.
Cancer Cytopathology|September 13, 2023
Don't SUMP it! Utility of PLAG1 immunocytochemistry in basaloid SUMP subcategoryMonica Sanchez-Avila, Youley Tjendra, Yiqin Zuo, et al.
Cancers|January 28, 2026
Tumor Growth Rate Predicts Pathological Outcomes in Breast Fibroepithelial Tumors: A Pilot Study and Review of LiteratureHisham F Bahmad, Adriana Falcon, Abdallah Araji, et al.
Annals of Surgical Oncology|March 18, 2022
Axillary Response to Neoadjuvant Therapy in Node-Positive, Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients: Predictors and Oncologic OutcomesOrli Friedman-Eldar, Tolga Ozmen, Salah James El Haddi, et al.
Cancer Cytopathology|July 1, 2022
Probability of malignancy as determined by ThyroSeq v3 genomic classifier varies according to the subtype of atypiaDavid C Gajzer, Youley Tjendra, Darcy A Kerr, et al.
Science Translational Medicine|November 5, 2025
DLL1-responsive PD-L1<sup>+</sup> tumor-associated macrophages promote endocrine resistance in breast cancerShailesh Singh, Claudia Weindorfer, Ajeya Nandi, et al.
Cancer Cytopathology|September 11, 2024
Parsing the thyroid cytopathology suspicious for malignancy diagnosis through molecular-derived risk of malignancy and other related parameters: Insights into nodule characteristics and practice patternsDavid Starr, Youley Tjendra, Jaylou M Velez Torres, et al.
Blood|November 26, 2015
Active IKKβ promotes the stability of GLI1 oncogene in diffuse large B-cell lymphomaNitin K Agarwal, Chae H Kim, Kranthi Kunkalla, et al.
Cancer Cytopathology|April 9, 2024
Atypia of undetermined significance and ThyroSeq v3-positive call rates as quality control metrics for cytology laboratory performanceOdille Mejia-Mejia, Andres Bravo-Gonzalez, Monica Sanchez-Avila, et al.
Pageof 3